Which women should have assessment of bone loss
- which woman should have a baseline assessment of bone loss
- patients with early invasive breast cancer should have a baseline dual energy X-ray absorptiometry (DEXA) scan to assess bone mineral density if they:
- are starting adjuvant aromatase inhibitor treatment
- have treatment-induced menopause
- are starting ovarian ablation/suppression therapy
- do not offer a DEXA scan to patients with early invasive breast cancer who are receiving tamoxifen alone, regardless of pretreatment menopausal status
- patients with early invasive breast cancer should have a baseline dual energy X-ray absorptiometry (DEXA) scan to assess bone mineral density if they:
Reference:
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.